Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation

Cell Metab. 2022 Oct 4;34(10):1514-1531.e7. doi: 10.1016/j.cmet.2022.08.003. Epub 2022 Aug 25.

Abstract

Gut intraepithelial lymphocytes (IELs) are thought to calibrate glucagon-like peptide 1 (GLP-1) bioavailability, thereby regulating systemic glucose and lipid metabolism. Here, we show that the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP-1 secretion and glucose homeostasis nor for the metabolic benefits of GLP-1R agonists (GLP-1RAs). Instead, the gut IEL GLP-1R is essential for the full effects of GLP-1RAs on gut microbiota. Moreover, independent of glucose control or weight loss, the anti-inflammatory actions of GLP-1RAs require the gut IEL GLP-1R to selectively restrain local and systemic T cell-induced, but not lipopolysaccharide-induced, inflammation. Such effects are mediated by the suppression of gut IEL effector functions linked to the dampening of proximal T cell receptor signaling in a protein-kinase-A-dependent manner. These data reposition key roles of the L cell-gut IEL GLP-1R axis, revealing mechanisms linking GLP-1R activation in gut IELs to modulation of microbiota composition and control of intestinal and systemic inflammation.

Keywords: GPCR; NASH; T cells; diabetes; glucagon-like peptide 1; immunology; inflammation; intestinal intraepithelial lymphocytes; microbiota; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • Gastrointestinal Microbiome*
  • Glucagon-Like Peptide 1 / metabolism
  • Glucagon-Like Peptide-1 Receptor
  • Glucose / metabolism
  • Humans
  • Inflammation
  • Intestines
  • Intraepithelial Lymphocytes* / metabolism
  • Receptors, Antigen, T-Cell

Substances

  • Blood Glucose
  • Glucagon-Like Peptide-1 Receptor
  • Receptors, Antigen, T-Cell
  • Glucagon-Like Peptide 1
  • Glucose

Grants and funding